Researchers have developed a new cancer treatment approach using engineered bacteria, offering a different way to deliver chemotherapy more precisely. In the study, scientists modified a probiotic strain of Escherichia coli Nissle 1917 so it could produce Romidepsin, an FDA-approved cancer drug. When tested in mice, the engineered bacteria naturally moved toward breast cancer tumors and […]

A new study maps the peripheral immune system of treatment-naive pancreatic ductal adenocarcinoma (PDAC) patients using high-dimensional spectral flow cytometry. By analyzing over 70 immune cell subsets, researchers identified changes in the immune system that distinguish PDAC patients from healthy individuals. This method measures 40+ surface proteins directly, offering detailed insights into functional immune states

A new study shows that the loss of the TP53 gene in pancreatic ductal adenocarcinoma (PDAC) changes how cancer cells manage acidity, helping them survive in harsh tumor environments. Normally, acidic conditions are toxic, but p53-deficient cells raise their internal pH and ramp up acid-exporting transporters like MCT4 to stay alive. These p53-lacking tumors also

Researchers have developed a new preclinical platform using patient-derived organoids (PDOs) and xenografts (PDX) to test treatments for pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC). They created 11 “mini-tumors” in the lab that closely mimic the structure, genetics, and biomarkers of the original patient tumors. These models remained stable for over a year,